Medical School, University of Sheffield, Sheffield, S10 2RX, UK.
Am J Pathol. 2010 Apr;176(4):1564-76. doi: 10.2353/ajpath.2010.090786. Epub 2010 Feb 18.
It is now established that bone marrow-derived myeloid cells regulate tumor angiogenesis. This was originally inferred from studies of human tumor biopsies in which a positive correlation was seen between the number of tumor-infiltrating myeloid cells, such as macrophages and neutrophils, and tumor microvessel density. However, unequivocal evidence was only provided once mouse models were used to examine the effects on tumor angiogenesis by genetically or pharmacologically targeting myeloid cells. Since then, identifying the exact myeloid cell types involved in this process has proved challenging because of myeloid cell heterogeneity and the expression of overlapping phenotypic markers in tumors. As a result, investigators often simply refer to them now as "bone marrow-derived myeloid cells." Here we review the findings of various attempts to phenotype the myeloid cells involved and discuss the therapeutic implications of correctly identifying-and thus being able to target-this proangiogenic force in tumors.
现在已经确定，骨髓来源的髓系细胞调节肿瘤血管生成。这最初是从对人类肿瘤活检的研究中推断出来的，在这些研究中，观察到浸润肿瘤的髓系细胞（如巨噬细胞和中性粒细胞）的数量与肿瘤微血管密度之间存在正相关关系。然而，只有在使用小鼠模型来检查通过遗传或药理学靶向髓系细胞对肿瘤血管生成的影响时，才提供了明确的证据。从那时起，由于髓系细胞异质性和肿瘤中重叠表型标志物的表达，确定参与这一过程的确切髓系细胞类型一直具有挑战性。因此，研究人员现在通常简单地将它们称为“骨髓来源的髓系细胞”。在这里，我们回顾了各种尝试对涉及的髓系细胞进行表型分析的发现，并讨论了正确识别——从而能够靶向——肿瘤中这种促血管生成力量的治疗意义。
